Concepedia

Muir Russell

MR

Statistics

Publications

8

Citations

431

H-Index

8

Active since

1991

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (Sweden)

AstraZeneca (United States)

AstraZeneca (Singapore)

PAREXEL International (United Kingdom)

Muir Russell is an author at AstraZeneca (United Kingdom) specializing in pharmacology, medicine, and pharmacodynamics.

Publications per year

1991–2020

8

Publications

8

Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure‐Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects

Robert S. Palmer, Jukka Mäenpää, Alexandra Jauhiainen et al. · Clinical Pharmacology & Therapeutics · 2018 · 98 citations · Full text

, , +16

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

Gvido Cebers, Robert Alexander, Samantha Budd Haeberlein et al. · Journal of Alzheimer s Disease · 2016 · 87 citations

, , +17

Pharmacokinetic and pharmacodynamic assessment of a five‐probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1

Graham Blakey, J.A. Lockton, John Perrett et al. · British Journal of Clinical Pharmacology · 2003 · 65 citations · Full text

, , +13

BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid Aβ Peptides

Kei Sakamoto, Shunji Matsuki, Kyoko Matsuguma et al. · The Journal of Clinical Pharmacology · 2017 · 61 citations

, , +17

Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction

Karin Nelander, Maria Lagerström‐Fermér, Carl Amilon et al. · Clinical and Translational Science · 2020 · 45 citations · Full text

, , +14

1–5 of 8